Literature DB >> 10082192

Neuroprotective effect of rasagiline, a selective monoamine oxidase-B inhibitor, against closed head injury in the mouse.

W Huang1, Y Chen, E Shohami, M Weinstock.   

Abstract

UNLABELLED: The potential neuroprotective effects of rasagiline, N-propargyl-1R-aminoindan, a selective monoamine oxidase-B inhibitor and its inactive enantiomer TVP 1022, N-propargyl-1S-aminoindan were assessed against the sequelae of closed head injury in the mouse. Injury was induced in the left hemisphere under ether anaesthesia. Rasagiline (0.2 and 1 mg/kg) or TVP1022 (1 and 2 mg/kg) injected 5 min after injury accelerated the recovery of motor function and spatial memory and reduced the cerebral oedema by about 40-50%, (P < 0.01). The neuroprotective effects on motor function and spatial memory, but not on cerebral oedema, were prevented by scopolamine (0.2 mg/kg). Daily injection of rasagiline (1 mg/kg) from day 3 after injury accelerated the recovery of spatial memory but not motor function.
CONCLUSIONS: Early administration of rasagiline or TVP1022 can reduce the immediate sequelae of brain injury. The mechanism of action does not appear to involve monoamine oxidase-B inhibition but could be mediated by the maintenance of cholinergic transmission in brain neurons.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10082192     DOI: 10.1016/s0014-2999(98)00929-7

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  26 in total

1.  Targeting Dopamine in Acute Traumatic Brain Injury.

Authors:  James W Bales; Anthony E Kline; Amy K Wagner; C Edward Dixon
Journal:  Open Drug Discov J       Date:  2010

2.  Rasagiline is neuroprotective in an experimental model of brain ischemia in the rat.

Authors:  Z Speiser; A Mayk; L Litinetsky; T Fine; A Nyska; E Blaugrund; S Cohen
Journal:  J Neural Transm (Vienna)       Date:  2006-12-21       Impact factor: 3.575

3.  Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B.

Authors:  M B Youdim; A Gross; J P Finberg
Journal:  Br J Pharmacol       Date:  2001-01       Impact factor: 8.739

Review 4.  Implications of co-morbidity for etiology and treatment of neurodegenerative diseases with multifunctional neuroprotective-neurorescue drugs; ladostigil.

Authors:  Moussa B H Youdim; Tamar Amit; Orit Bar-Am; Orly Weinreb; Mara Yogev-Falach
Journal:  Neurotox Res       Date:  2006-12       Impact factor: 3.911

Review 5.  Movement disorders: neurodevelopment and neurobehavioural expression.

Authors:  T Archer; R J Beninger
Journal:  J Neural Transm (Vienna)       Date:  2006-10-06       Impact factor: 3.575

Review 6.  The role of rasagiline in the treatment of Parkinson's disease.

Authors:  Julie Leegwater-Kim; Elena Bortan
Journal:  Clin Interv Aging       Date:  2010-05-25       Impact factor: 4.458

7.  Spotlight on rasagiline in Parkinson's disease.

Authors:  Vicki Oldfield; Gillian M Keating; Caroline M Perry
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

Review 8.  Neuroprotective strategies in Parkinson's disease : an update on progress.

Authors:  Silvia Mandel; Edna Grünblatt; Peter Riederer; Manfred Gerlach; Yona Levites; Moussa B H Youdim
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

Review 9.  Rasagiline promotes regeneration of substantia nigra dopaminergic neurons in post-MPTP-induced Parkinsonism via activation of tyrosine kinase receptor signaling pathway.

Authors:  Silvia A Mandel; Yotam Sagi; Tamar Amit
Journal:  Neurochem Res       Date:  2007-08-16       Impact factor: 3.996

Review 10.  Recent developments in multiple system atrophy.

Authors:  Gregor K Wenning; Nadia Stefanova
Journal:  J Neurol       Date:  2009-05-27       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.